MOR / MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

MorphoSys AG's American depositary receipts MOR, +1.38% gained 2% premarket on Wednesday after the biopharma company said its investigational treatmen more_horizontal

MorphoSys AG (NASDAQ:MOR ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Inv more_horizontal

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarte more_horizontal

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this more_horizontal

MorphoSys had said it planned to cut preclinical programs and trim its workforce. The company said it expected top-line results for a myelofibrosis dr more_horizontal

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the f more_horizontal

MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's tw more_horizontal

MorphoSys caps off a year of bad news with the departure of its CFO. With gantenerumab done for now, the key P&L driver will be Monjuvi, a product tha more_horizontal